The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes.

"CONFLICT OF INTEREST STATEMENT Outside the submitted work, J.S.L. reports personal fees from Pfizer, AstraZeneca and Bristol-Myers Squibb; P.B.M. reports personal fees and/or non-financial support from Vifor, Napp, Pharmacosmos, AstraZeneca, Astellas and Novartis, and grants from Boehringer Ingelheim; N.N.L. reports personal fees and non-financial support from Roche, Pfizer, Novartis, AstraZeneca, Pharmacosmos and Vifor Pharma, and grant support from Roche Diagnostics, AstraZeneca and Boehringer (all paid to the University of Glasgow, his employing institution). R.J.J. reports research support from Clovis, Astellas, Exelixis, AstraZeneca and Roche, and honoraria from Clovis, Astellas, AstraZeneca, Roche, Ipsen, Bristol-Myers-Squibb, Pfizer, Merck Serono, Merck Sharp Dohme, Janssen, Bayer and Novartis."

"FUNDING J.S.L. is funded by a Chief Scientist Office (Scotland) Postdoctoral Lectureship (PCL/20/10). S.M.H is supported by NIH grant K08 DK118120 and Mayo Clinic K2R award."